GuidelinesOther guideline
Musculoskeletal System
Baclofen Botulinum toxin Zoledronate Zoledronate, Ibandronate Zoledronate, IV, Ibandronate, IV Alendronate ATC Code M03BX01 Medicine Baclofen Indication Spasticity NEMLC Recommendation Not Approved Review Indicators New evidence of clinically relevant efficacy Date Ratified 25 June 2015 ATC Code M03AX01 Medicine Botulinum toxin Indication Focal dystonias NEMLC Recommendation Ap
Zoledronate, IV, Ibandronate, IV
| ATC Code | M03BX01 |
| Medicine | Baclofen |
| Indication | Spasticity |
| NEMLC Recommendation | Not Approved |
| Review Indicators | New evidence of clinically relevant efficacy |
| Date Ratified | 25 June 2015 |
| ATC Code | M03AX01 |
| Medicine | Botulinum toxin |
| Indication | Focal dystonias |
| NEMLC Recommendation | Approved for use in carefully selected patients Only to be administered by suitably experienced practitioners |
| Review Indicators | New evidence with clinical relevant/ well defined endpoints and well described dosage regimens |
| Date Ratified | 30 June 2016 |
| ATC Code | M03AX01 |
| Medicine | Botulinum toxin |
| Indication | Spastic cerebral palsy |
| NEMLC Recommendation | Not Approved |
| Review Indicators | New evidence with clinical relevant/ well defined endpoints and well described dosage regimens |
| Date Ratified | Re-review: 30 June 2016 |
| ATC Code | M05BA08 |
| Medicine | Zoledronate |
| Indication | Multiple myeloma associated bone disease |
| NEMLC Recommendation | Approved |
| Review Indicators |
New evidence of efficacy or safety |
| Date Ratified | 12 October 2023 (Previously reviewed 25 July 2013) |
| ATC Code | M05BA |
| Medicine | Bisphosphonates: Zoledronate, Ibandronate |
| Indication | Hypercalcaemia of malignancy |
| NEMLC Recommendation | Approved |
| Review Indicators |
New evidence of efficacy or safety |
| Date Ratified | 12 October 2023 (Previously reviewed September 2007: pamidronate approved but agent subsequently discontinued) |
| ATC Code | M05BA |
| Medicine | Bisphosphonates, IV: Zoledronate, IV, Ibandronate, IV |
| Indication | Secondary prevention of osteoporosis associate fractures |
| NEMLC Recommendation | Approved For patients unable to tolerate oral bisphosphonates, or in patients where oral bisphosphonates are contraindicated |
| Review Indicators |
n/a |
| Date Ratified | 14 March 2024 |
| ATC Code | M05BA04 |
| Medicine | Alendronate |
| Indication | Osteogenesis imperfect |
| NEMLC Recommendation | Not Approved |
| Review Indicators | Evidence of efficacy and safety |
| Date Ratified | 25 July 2013 |
| ATC Code | M05BA04 |
| Medicine | Alendronate |
| Indication | Paget’s |
| NEMLC Recommendation | Not Approved |
| Review Indicators | - New high quality adequately powered trials providing evidence addressing clinically important parameters - New safety concerns |
| Date Ratified | September 2007 |